← Leaderboards
Patricio Sepulveda
Amplo Biotechnology, Inc.
$5,506,739
Attributed
$6,157,361
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,157,361 · 2
By mechanism
R44$4,856,116 · 1
R42$1,301,245 · 1
Top collaborators
- Ricardo Anibal Maselli3 shared
Others in their field
Other Emerging Leaders on “Ensure”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$142,551,806
Research focus
EnsureDefectDoseDisease ProgressionCollaborationsCongenital Myasthenic SyndromesClinical PracticeDesignClinical DevelopmentDisease ManagementChildChokingAssay DevelopmentAdultChronicBeta-2 Adrenergic ReceptorsAffectDependenceAdrenergic AgonistsCardiomyopathiesBiotechnologyAlbuterolAcetylcholinesterase InhibitorsEnteral Feeding
Grant awards (7)
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes$601,044
R42 · FY2025 · NS · contact PI
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$2,999,358
R44 · FY2024 · NS · contact PI
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes$207,090
R42 · FY2024 · NS · contact PI
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes$493,111
R42 · FY2023 · NS · contact PI
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$144,102
R44 · FY2023 · NS · contact PI
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$1,458,731
R44 · FY2022 · NS · contact PI
Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes$253,925
R44 · FY2021 · NS · contact PI